Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $10.29, but opened at $8.82. Ginkgo Bioworks shares last traded at $9.82, with a volume of 1,454,847 shares trading hands.
Ginkgo Bioworks Price Performance
The stock has a fifty day moving average price of $11.49. The stock has a market cap of $471.04 million, a P/E ratio of -0.63 and a beta of 1.16.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in shares of Ginkgo Bioworks during the fourth quarter worth $29,000. KBC Group NV purchased a new stake in Ginkgo Bioworks during the 4th quarter valued at about $31,000. KLP Kapitalforvaltning AS purchased a new stake in Ginkgo Bioworks during the 4th quarter valued at about $46,000. Mercer Global Advisors Inc. ADV acquired a new stake in Ginkgo Bioworks in the 4th quarter valued at about $116,000. Finally, Palumbo Wealth Management LLC purchased a new position in Ginkgo Bioworks in the 4th quarter worth approximately $144,000. 78.63% of the stock is owned by institutional investors and hedge funds.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
